Evolus, Inc.

EOLS

$9.05

-0.11%

2026-09-04 11:55:31 EDT+$0.00

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their ...

Supply Chain of EOLS

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Daewoong Pharmaceutical Co., Ltd.

Symatese

Unidentified raw material suppliers to Daewoong (peptones, culture media, fermentation inputs)

Unidentified hyaluronic acid & BDDE suppliers to Symatese

Daewoong Pharmaceutical Co., Ltd.

KRX:069620

Sole manufacturer and exclusive supplier of Jeuveau®/Nuceiva® (prabotulinumtoxinA). Holds the Drug Master File and manufactures via fermentation of Clostridium botulinum in a state-of-the-art facility in South Korea. License & Supply Agreement since 2013, with multiple amendments.

Symatese

Manufacturer of Evolysse™ and Estyme® hyaluronic acid dermal fillers using proprietary Cold-X™ crosslinking technology. Also serves as exclusive distributor of Nuceiva® in France and Estyme® fillers across Europe/UK. Privately held French company headquartered in Chaponost, France.

Unidentified raw material suppliers to Daewoong (peptones, culture media, fermentation inputs)

Suppliers of biological culture media, amino acids, and specialized raw materials for botulinum toxin fermentation process. Not publicly disclosed by Daewoong or Evolus.

Unidentified hyaluronic acid & BDDE suppliers to Symatese

Suppliers of pharmaceutical-grade sodium hyaluronate and 1,4-butanediol diglycidyl ether (BDDE) crosslinker used in HA filler manufacturing. Not publicly disclosed.

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

Evolus Direct Sales Force (U.S. Market)

Clarion Medical Technologies Inc.

NOVVIA GmbH

GP Dermal Solution

Symatese (France distribution arm)

Wigmore Medical Ltd

HealthXChange Pharmacy UK Ltd

Medfx

Evolus Direct Sales Force (U.S. Market)

Evolus sells Jeuveau® and Evolysse™ directly to aesthetic medical practitioners (dermatologists, plastic surgeons, medspas) in the United States via its own specialized sales force. ~92% of total revenue comes from U.S. direct sales. · 92.0%

Clarion Medical Technologies Inc.

Exclusive distribution partner in Canada for Jeuveau®/Nuceiva® since October 2019. Clarion is a leading Canadian provider of medical and aesthetic equipment and consumables. Owned by Richards Packaging Income Fund.

NOVVIA GmbH

Distribution partner in Germany and Austria for Nuceiva® since February 2023. Leading supplier of specialist products to aesthetics practitioners in the DACH region.

GP Dermal Solution

Distribution partner in Italy for Nuceiva® since June 2023. Italian company specializing in cosmetic, medical, and wellness sector distribution.

Symatese (France distribution arm)

Distribution partner for Nuceiva® in France since July 2025. Also the distributor for Estyme® dermal fillers across Europe and UK under a December 2023 exclusive licensing agreement. Symatese sub-licenses distribution rights to a subsidiary in France.

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

AbbVie Inc.

Galderma Group AG

Revance Therapeutics, Inc.

Hugel, Inc.

Daewoong Pharmaceutical Co., Ltd.

AbbVie Inc.

NYSE:ABBV

Owner of Allergan Aesthetics and Botox® Cosmetic — the dominant competitor in the aesthetic neuromodulator market. AbbVie's Botox franchise is the market leader that Evolus directly competes with via Jeuveau. Also a former litigation counterparty (settled 2021).

Galderma Group AG

SWX:GALD

Swiss aesthetics pure-play with Dysport® (botulinum toxin competitor to Jeuveau) and a broad HA filler portfolio (Restylane® family). Most comparable diversified aesthetics company with both toxin and filler product lines.

Revance Therapeutics, Inc.

NASDAQ:RVNC

U.S.-based competitor with Daxxify® (botulinum toxin) and the RHA® Collection of dermal fillers. Similar business model as a pure-play aesthetics company focused on innovation in neuromodulators and fillers.

Hugel, Inc.

KRX:145020

South Korean medical aesthetics company competing with Botulax® (botulinum toxin) and fillers. Shares the same Korean manufacturing ecosystem as Daewoong and competes in overlapping international markets.

Daewoong Pharmaceutical Co., Ltd.

KRX:069620

Evolus's critical sole-source upstream supplier. Daewoong's operational health, regulatory compliance, capacity expansion, and corporate strategy directly determine Evolus's ability to manufacture and supply Jeuveau/Nuceiva.

Geographic

Region-level exposures that can distort the supply network.

Geographic

South Korea

France

United States

Daewoong Pharmaceutical Co., Ltd.

Symatese

Evolus Direct Sales Force (U.S.)

South Korea

Sole manufacturing source for core product (toxin); trade route dependency for U.S. and international supply

Daewoong Pharmaceutical Co., Ltd.KRX:069620Sole manufacturer of Jeuveau® and Nuceiva®; all finished product exported from South Korea to the U.S., Canada, Europe, and Australia

France

Sole manufacturing source for dermal filler portfolio; also serves as European distribution hub

SymateseManufacturer of Evolysse™ and Estyme® HA fillers; distributor of Nuceiva® in France

United States

Primary end-market (~92% of revenue); regulatory dependency on FDA for product approvals and import clearance

Evolus Direct Sales Force (U.S.)Direct commercial operations serving ~55%+ account penetration among U.S. aesthetic practitioners

Canada / Europe / Australia

International growth markets (~8% of revenue); subject to local regulatory approvals, import controls, and distributor performance

Clarion Medical Technologies Inc.Exclusive Canadian distributor

NOVVIA GmbHGerman/Austrian distributor

GP Dermal SolutionItalian distributor

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Manufacturing

Critical

Evolus is 100% reliant on Daewoong Pharmaceutical (South Korea) as the sole manufacturer of its core product Jeuveau®/Nuceiva®. There is no approved backup manufacturer for the toxin. Any disruption at Daewoong's facility — due to regulatory action, quality issues, trade disputes, geopolitical tension, or IP litigation — would halt all toxin revenue (~92% of total revenue).

Manufacturing

High

Evolus relies on Symatese (France) as the sole manufacturer of its HA dermal fillers (Evolysse™/Estyme®). While fillers represent a smaller revenue share (~7.6% in FY2025), this dependency is growing as the product line expands.

Customer

High

Approximately 92% of FY2025 revenue was derived from U.S. sales. International markets (Canada, Europe, Australia) contributed only ~8%. While international expansion is a strategic priority, the company remains highly dependent on the U.S. aesthetic market and its direct sales force effectiveness.

Equipment

Medium

Daewoong's botulinum toxin manufacturing requires specialized fermentation, purification, and fill-finish equipment. Key equipment suppliers (e.g., bioreactor systems, chromatography columns, aseptic filling lines) are concentrated among a few global life sciences equipment vendors. Not directly sourced by Evolus but critical to the sole-source supplier's operations.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

Global Toxin (Jeuveau® / Nuceiva®)

92.4%

$0.3B

Entirely dependent on Daewoong Pharmaceutical (South Korea) as sole manufacturer and supplier; any disruption in Daewoong's facility, regulatory approvals, or trade/logistics between Korea and target markets would halt all toxin revenue.

Injectable HA Dermal Fillers (Evolysse™ / Estyme®)

7.6%

$0.0B

Manufactured by Symatese (France); growing contributor expected to reach 10-12% of total revenue in 2026. Cold-X™ technology differentiator; single-source dependency on Symatese.

Service Revenue (Distribution & Royalties)

0.7%

$0.0B

Primarily relates to distribution arrangements (e.g., Canada via Clarion Medical); minor but recurring contribution.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Evolus, Inc.

Supply Chain of EOLS

Upstream

Daewoong Pharmaceutical Co., Ltd.

Symatese

Unidentified raw material suppliers to Daewoong (peptones, culture media, fermentation inputs)

Unidentified hyaluronic acid & BDDE suppliers to Symatese

Downstream

Evolus Direct Sales Force (U.S. Market)

Clarion Medical Technologies Inc.

NOVVIA GmbH

GP Dermal Solution

Symatese (France distribution arm)

Wigmore Medical Ltd

HealthXChange Pharmacy UK Ltd

Medfx

View More

Proxies

AbbVie Inc.

Galderma Group AG

Revance Therapeutics, Inc.

Hugel, Inc.

Daewoong Pharmaceutical Co., Ltd.

Geographic

South Korea

France

United States

View More

Supply Chain of EOLS

Upstream

Daewoong Pharmaceutical Co., Ltd.

Symatese

Unidentified raw material suppliers to Daewoong (peptones, culture media, fermentation inputs)

Unidentified hyaluronic acid & BDDE suppliers to Symatese

Downstream

Evolus Direct Sales Force (U.S. Market)

Clarion Medical Technologies Inc.

NOVVIA GmbH

GP Dermal Solution

Symatese (France distribution arm)

Wigmore Medical Ltd

HealthXChange Pharmacy UK Ltd

Medfx

View More

Proxies

AbbVie Inc.

Galderma Group AG

Revance Therapeutics, Inc.

Hugel, Inc.

Daewoong Pharmaceutical Co., Ltd.

Geographic

South Korea

France

United States

View More